Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | PPARD | Q03181 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.50 |
| ▸ | CNR1 | P21554 | 8/20 | 0.47 |
| ▸ | CNR2 | P34972 | 8/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13008056 | 0.90 | MCL1 (0.47) | FFAR1PPARGPPARDPPARAFFAR4 | |
| SCHEMBL13490817 | 0.84 | CNR1 (0.51) | FFAR1PPARGPPARDPPARACNR1 | |
| SCHEMBL13490815 | 0.84 | BRD4 (0.47) | FFAR1PPARGPPARDPPARACNR1 | |
| SCHEMBL19411075 | 0.83 | FFAR1 (0.56) | FFAR1PPARGPPARDPPARAFFAR4 | |
| SCHEMBL28634310 | 0.82 | MCL1 (0.57) | FFAR1PLA2G2AMCL1 | |
| SCHEMBL22578056 | 0.81 | MCL1 (0.61) | FFAR1PPARGPPARDPPARAFFAR4 | |
| SCHEMBL12051638 | 0.80 | RXRA (0.47) | FFAR1FFAR4 | |
| SCHEMBL88959 | 0.78 | ALDH1A1 (0.44) | CNR1CNR2 | |
| SCHEMBL13490807 | 0.78 | CNR1 (0.44) | CNR1CNR2 | |
| SCHEMBL88961 | 0.78 | ALDH1A1 (0.48) | CNR1CNR2PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | REN, PAH, ACE | FFAR1 4572/4885PPARG 1821/4885PPARD 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.